Equities analysts expect ConforMIS, Inc. (NASDAQ:CFMS) to report sales of $17.69 million for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for ConforMIS’s earnings. The highest sales estimate is $18.00 million and the lowest is $17.29 million. ConforMIS posted sales of $18.64 million in the same quarter last year, which indicates a negative year over year growth rate of 5.1%. The business is scheduled to announce its next quarterly earnings report after the market closes on Wednesday, November 1st.

On average, analysts expect that ConforMIS will report full-year sales of $17.69 million for the current year, with estimates ranging from $75.79 million to $77.14 million. For the next fiscal year, analysts forecast that the firm will post sales of $83.55 million per share, with estimates ranging from $81.35 million to $85.74 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for ConforMIS.

ConforMIS (NASDAQ:CFMS) last released its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.08. ConforMIS had a negative net margin of 72.87% and a negative return on equity of 66.61%. The firm had revenue of $18.50 million during the quarter, compared to the consensus estimate of $19.34 million. During the same quarter in the prior year, the firm earned ($0.34) EPS. The company’s revenue for the quarter was down 4.1% on a year-over-year basis.

Several analysts recently commented on CFMS shares. Zacks Investment Research cut shares of ConforMIS from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of ConforMIS in a research note on Tuesday, June 20th. BTIG Research reiterated a “hold” rating on shares of ConforMIS in a research note on Sunday, July 16th. Deutsche Bank AG reiterated a “hold” rating and issued a $5.00 price objective (down previously from $6.00) on shares of ConforMIS in a research note on Friday, August 4th. Finally, ValuEngine upgraded shares of ConforMIS from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $6.71.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN lifted its stake in shares of ConforMIS by 1.8% in the first quarter. Wells Fargo & Company MN now owns 53,930 shares of the medical instruments supplier’s stock valued at $282,000 after purchasing an additional 935 shares during the period. American International Group Inc. lifted its stake in shares of ConforMIS by 7.0% in the first quarter. American International Group Inc. now owns 22,009 shares of the medical instruments supplier’s stock valued at $115,000 after purchasing an additional 1,448 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of ConforMIS by 21.4% in the second quarter. The Manufacturers Life Insurance Company now owns 37,121 shares of the medical instruments supplier’s stock valued at $158,000 after purchasing an additional 6,535 shares during the period. Rhumbline Advisers lifted its stake in shares of ConforMIS by 21.8% in the second quarter. Rhumbline Advisers now owns 44,782 shares of the medical instruments supplier’s stock valued at $192,000 after purchasing an additional 8,017 shares during the period. Finally, State Street Corp lifted its stake in shares of ConforMIS by 1.5% in the second quarter. State Street Corp now owns 594,583 shares of the medical instruments supplier’s stock valued at $2,550,000 after purchasing an additional 8,693 shares during the period. Hedge funds and other institutional investors own 33.60% of the company’s stock.

ConforMIS (CFMS) opened at 3.46 on Wednesday. ConforMIS has a 52-week low of $3.22 and a 52-week high of $10.16. The company’s 50 day moving average is $3.71 and its 200 day moving average is $3.71. The firm’s market cap is $155.13 million.

WARNING: “$17.69 Million in Sales Expected for ConforMIS, Inc. (CFMS) This Quarter” was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/18/17-69-million-in-sales-expected-for-conformis-inc-cfms-this-quarter-3.html.

About ConforMIS

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Get a free copy of the Zacks research report on ConforMIS (CFMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.